Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RMD-007
- Development stage
- Unknown
- Lead developer
- Remedium Bio
- Modality
- Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
RMD-007 is a clinical-stage adjustable gene therapy candidate being developed by Remedium Technologies for the treatment of metabolic disorders. Utilizing the company's proprietary Prometheus™ platform, RMD-007 is designed to overcome the limitations of traditional gene therapies by allowing for dose-responsive regulation of transgene expression. The therapy is delivered using either adeno-associated virus (AAV) or lipid nanoparticle (LNP) vectors. While the specific therapeutic transgene and molecular target have not been disclosed, the asset is currently in Phase 1 clinical development, targeting a range of metabolic conditions.
Beyond the preview
Go deeper on RMD-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RMD-007.